

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4940321

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JIPING FU	04/13/2018
WOOSEOK HAN	04/13/2018
SUBRAMANIAN KARUR	04/13/2018
PEICHAO LU	04/13/2018
KEITH BRUCE PFISTER	04/13/2018
JOSEPH MICHAEL YOUNG	04/13/2018
RECEIVING PARTY DATA	
Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Street Address:	250 MASSACHUSETTS AVENUE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15965172
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(510) 879-9719
Email:	lisa.nash@novartis.com
Correspondent Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Address Line 1:	5300 CHIRON WAY
Address Line 4:	EMERYVILLE, CALIFORNIA 94608
ATTORNEY DOCKET NUMBER:	PAT057714-US-NP
NAME OF SUBMITTER:	LISA NASH
SIGNATURE:	/lisa nash/
DATE SIGNED:	05/01/2018
Total Attachments: 21	

source=PAT057714-US-NP Assignment Step I#page1.tif
source=PAT057714-US-NP Assignment Step I#page2.tif
source=PAT057714-US-NP Assignment Step I#page3.tif
source=PAT057714-US-NP Assignment Step I#page4.tif
source=PAT057714-US-NP Assignment Step I#page5.tif
source=PAT057714-US-NP Assignment Step I#page6.tif
source=PAT057714-US-NP Assignment Step I#page7.tif
source=PAT057714-US-NP Assignment Step I#page8.tif
source=PAT057714-US-NP Assignment Step I#page9.tif
source=PAT057714-US-NP Assignment Step I#page10.tif
source=PAT057714-US-NP Assignment Step I#page11.tif
source=PAT057714-US-NP Assignment Step I#page12.tif
source=PAT057714-US-NP Assignment Step I#page13.tif
source=PAT057714-US-NP Assignment Step I#page14.tif
source=PAT057714-US-NP Assignment Step I#page15.tif
source=PAT057714-US-NP Assignment Step I#page16.tif
source=PAT057714-US-NP Assignment Step I#page17.tif
source=PAT057714-US-NP Assignment Step I#page18.tif
source=PAT057714-US-NP Assignment Step I#page19.tif
source=PAT057714-US-NP Assignment Step I#page20.tif
source=PAT057714-US-NP Assignment Step I#page21.tif

ASSIGNMENT

This Assignment Agreement is entered into by and between

Jiping FU	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Wooseok HAN	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 United States of America
Subramanian KARUR	citizen of India	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Peichao LU	citizen of China	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Keith Bruce PFISTER	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 5300 Chiron Way Emeryville, CA 94608 USA United States of America
Joseph Michael YOUNG	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America

(hereinafter "Inventor(s)"), and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.**, 250 Massachusetts Ave, Cambridge, MA 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for Biomedical Research Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS

[Patent Application Reference: PAT057714]

and filed in the United States Patent and Trademark Office on 27 April 2018 and accorded Application Number 15/965,172 and/or filed as a PCT International Application on 27 April 2018 and accorded International Patent Application Number PCT/IB2018/052921;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and

divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect.

The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the laws of the state of Delaware.


This Assignment is effective as from the earliest priority date as stated above.

Executed this 13 day of April, 2018

BY 
Jiping FU

Witnessed by:


Name: Kelly Horan
Address: 166 St. Helena Ct.
Danville, CA 94526


Name: Gary Sharkey
Address: 166 St. Helena Ct.
Danville, CA 94526

Executed this _____ day of _____, 2018

BY _____
Wooseok HAN

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2018

BY _____
Subramanian KARUR

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Peichao LU

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Keith Bruce PFISTER

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Joseph Michael YOUNG


Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608


NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

Executed this 17th day of April, 2018

BY 
Mark Hopkins
Authorized Signatory

Witnessed by:


James Grant
c/o 5300 Chiron Way
Emeryville, CA 94608


Lisa Nash
c/o 5300 Chiron Way
Emeryville, CA 94608

ASSIGNMENT

This Assignment Agreement is entered into by and between

Jiping FU	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Wooseok HAN	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 United States of America
Subramanian KARUR	citizen of India	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Peichao LU	citizen of China	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Keith Bruce PFISTER	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 5300 Chiron Way Emeryville, CA 94608 USA United States of America
Joseph Michael YOUNG	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America

(hereinafter "Inventor(s)"), and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.**, 250 Massachusetts Ave, Cambridge, MA 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for Biomedical Research Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
[Patent Application Reference: PAT057714]

and filed in the United States Patent and Trademark Office on 27 April 2018 and
accorded Application Number 15/1905,172 and/or filed as a PCT International
Application on 27 April 2018 and accorded International Patent Application Number
PCT/IB2018/052921;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and

divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect.

The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the state of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 2018

BY _____
Jiping FU

Witnessed by:


Name:
Address:


Name:
Address:

Executed this 13 day of April, 2018

BY 
Woosok HAN

Witnessed by:


Name: Victoria L. Smith
Address: 700 Main St
Cambridge, MA 02139


Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139

Executed this _____ day of _____, 2018

BY _____
Subramanian KARUR

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Peichao LU

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Keith Bruce PFISTER

Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this _____ day of _____, 2018

BY _____
Joseph Michael YOUNG


Witnessed by:

Name:
c/o 5300 Chiron Way
Emeryville, CA 94608


Name:
c/o 5300 Chiron Way
Emeryville, CA 94608


NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

Executed this 13 day of April, 2018

BY 
Authorized Signatory

Witnessed by:


Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139


Name: Victoria L. Smith
Address: 700 Main St.
Cambridge, MA 02139

ASSIGNMENT

This Assignment Agreement is entered into by and between

Jiping FU	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Wooseok HAN	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 United States of America
Subramanian KARUR	citizen of India	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Peichao LU	citizen of China	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America
Keith Bruce PFISTER	citizen of United States of America	Novartis Institutes for BioMedical Research, Inc. 5300 Chiron Way Emeryville, CA 94608 USA United States of America
Joseph Michael YOUNG	citizen of United States of America	Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, CA 94608 United States of America

(hereinafter "Inventor(s)"), and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.**, 250 Massachusetts Ave, Cambridge, MA 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to Novartis Institutes for Biomedical Research Inc. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS

[Patent Application Reference: PAT057714]

and filed in the United States Patent and Trademark Office on 27 April 2018 and accorded Application Number 15/965,172 and/or filed as a PCT International Application on 27 April 2018 and accorded International Patent Application Number PCT/IB2018/052921;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and

divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect.

The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the state of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this _____ day of _____, 2018

BY _____
Jiping FU

Witnessed by:

Name:
Address:

Name:
Address:

Executed this _____ day of _____, 2018

BY _____
Wooseok HAN

Witnessed by:

Name:
Address:

Name:
Address:

Executed this 13th day of April, 2018


BY 
Subramanian KARUR

Witnessed by:


Name: WILLIAM JOSE
c/o 5300 Chiron Way
Emeryville, CA 94608



Name: VIVIAN TRAN
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this 13 day of April, 2018

BY 
Peichao LU

Witnessed by:



Name: JO ANN HUNTER
c/o 5300 Chiron Way
Emeryville, CA 94608



Name: WILLIAM JOSE
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this 13th day of April, 2018


BY 
Keith Bruce PFISTER

Witnessed by:


Name: JO ANN HUNTER
c/o 5300 Chiron Way
Emeryville, CA 94608


Name: WILLIAM JOSE
c/o 5300 Chiron Way
Emeryville, CA 94608

Executed this 13 day of April, 2018

BY 
Joseph Michael YOUNG


Witnessed by:


Name: Lisa J. Jost
c/o 5300 Chiron Way
Emeryville, CA 94608


Name: VIVIAN TRAN
c/o 5300 Chiron Way
Emeryville, CA 94608

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.

Executed this 17th day of April, 2018

BY 
Mark Hopkins
Authorized Signatory

Witnessed by:


James Grant
c/o 5300 Chiron Way
Emeryville, CA 94608


Lisa Nash
c/o 5300 Chiron Way
Emeryville, CA 94608